FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2976004908> ?p ?o ?g. }

• W2976004908 abstract "Abstract Introduction This is a complex case of a 50-year-old lady who presented with peripheral synovitis, fever and rash. She developed ulcerative skin lesions, proximal muscle weakness and pulmonary fibrosis. Case description A 50-year-old woman presented with a 6-week history of joint pain and swelling, an erythematous rash and fever. No preceding illness. She had fibromyalgia and chronic low back pain. She had several courses of prednisolone 20mg for presumed reactive arthritis with no benefit. She was a non-smoker, did not drink alcohol and was unemployed. She had florid symmetrical synovitis affecting MCPs, PIPs, wrists, ankles and knees. She had an erythematous rash across her face, chest and upper arms. She was pyrexic at night when her skin became inflamed. ESR-35 and CRP-13. RF, anti-CCP, ANA, ANCA, ACE and ASOT titre were negative. U&E was normal. LFTs were elevated with GGT-113, ALP-143, AST-432 and ALT-281. CK-33, LDH-367 and ferritin-2573. CXR, urine dip and liver screen were normal. USS abdomen, ECHO, CT CAP and PFTs were normal. Skin biopsy showed features of interface dermatitis. Extended myositis panel was negative. MRI of thighs showed active myositis. Muscle biopsy was insufficient. Tumour markers, mammogram, USS of breasts, OGD and colonoscopy were normal. The working diagnosis was dermatomyositis. She was treated with hydroxychloroquine and prednisolone 60mg with little benefit. She had three pulses of IV methylprednisolone with good benefit for joints. Azathioprine was not tolerated. Skin worsened and she was treated with 5 days IV immunoglobulins. She developed ulcerating skin lesions and swabs confirmed pseudomonas which was treated with ciprofloxacin and topical steroids. Dapsone caused haemolysis. She was switched to mycophenolate. Joints flared when prednisolone was reduced below 60mg and she was treated with rituximab. She developed proximal muscle weakness. Repeat MRI of thighs showed further progression of active myositis. Extended myositis panel confirmed Anti-MDA5 myositis. HRCT showed established pulmonary fibrosis. The myositis tertiary referral centre recommended IV cyclophosphamide. She responded well with improvement in joints and skin and prednisolone was weaned. Discussion This was a refractory case of anti-MDA 5 myositis which failed to respond to multiple immunosuppressive treatments. The patient failed high dose oral steroids initially and therefore treatment was escalated to IV methylprednisolone. Her joint disease responded but unfortunately her skin deteriorated. We treated with IV immunoglobulins with no benefit. She was unable to tolerate azathioprine and was switched to mycophenolate as an alternative steroid sparing agent. Despite steroids, mycophenolate and immunoglobulins her disease progressed with worsening myositis, ulcerating skin lesions and pulmonary fibrosis. Rituximab is a well-recognised potential treatment option for patients with myositis resistant to conventional treatment. The extended myositis panel revealed anti-MDA5 myositis, which is associated with rapidly progressive interstitial lung disease and ulcerative skin lesions. These are case reports in Rheumatology in 2017 which describe successful treatment with rituximab for anti-MDA5 myositis. However in this particular case, our patient failed to respond to rituximab. Cyclophosphamide is reserved for severe cases of myositis with rapidly progressive lung disease. We took the opportunity to discuss this case with the tertiary myositis referral centre in Liverpool and they advised to proceed with cyclophosphamide with good benefit. This was an interesting case of anti MDA 5 myositis. The initial presentation was not classical for an inflammatory myopathy with peripheral synovitis, fever and a rash. This patient’s signs and symptom evolved with development of muscle weakness and pulmonary fibrosis. CK was normal and this highlights the importance of checking other muscle enzymes in cases of suspected myositis. An extended myositis panel is also invaluable and helped to confirm the diagnosis in this particular case. Key learning points It is important to consider anti-MDA5 dermatomyositis particularly if patient presents with polyarthritis and ulcerative skin lesions. CK may be normal in myositis and it is important to check other muscle enzymes. There are five muscle enzymes to consider in cases of suspected myositis including CK, aldolase, AST, ALT and LDH. It is important to consider myositis if a patient presents with raised ALT and AST without underlying liver disease. If the Royal Free myositis panel is negative, consider sending research myositis panel to Bath. Conflicts of interest The authors have declared no conflicts of interest." @default.
• W2976004908 created "2019-10-03" @default.
• W2976004908 creator A5009628592 @default.
• W2976004908 creator A5011295271 @default.
• W2976004908 date "2019-09-01" @default.
• W2976004908 modified "2023-10-14" @default.
• W2976004908 title "7. Anti-MDA5 associated dermatomyositis" @default.
• W2976004908 doi "https://doi.org/10.1093/rap/rkz030.006" @default.
• W2976004908 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6761434" @default.
• W2976004908 hasPublicationYear "2019" @default.
• W2976004908 type Work @default.
• W2976004908 sameAs 2976004908 @default.
• W2976004908 citedByCount "1" @default.
• W2976004908 countsByYear W29760049082020 @default.
• W2976004908 crossrefType "journal-article" @default.
• W2976004908 hasAuthorship W2976004908A5009628592 @default.
• W2976004908 hasAuthorship W2976004908A5011295271 @default.
• W2976004908 hasBestOaLocation W29760049081 @default.
• W2976004908 hasConcept C126322002 @default.
• W2976004908 hasConcept C141071460 @default.
• W2976004908 hasConcept C16005928 @default.
• W2976004908 hasConcept C2775934546 @default.
• W2976004908 hasConcept C2776715498 @default.
• W2976004908 hasConcept C2776760755 @default.
• W2976004908 hasConcept C2778570526 @default.
• W2976004908 hasConcept C2778720950 @default.
• W2976004908 hasConcept C2778751314 @default.
• W2976004908 hasConcept C2779123688 @default.
• W2976004908 hasConcept C2779134260 @default.
• W2976004908 hasConcept C2779999465 @default.
• W2976004908 hasConcept C2780439664 @default.
• W2976004908 hasConcept C2781232998 @default.
• W2976004908 hasConcept C3008058167 @default.
• W2976004908 hasConcept C524204448 @default.
• W2976004908 hasConcept C71924100 @default.
• W2976004908 hasConcept C90924648 @default.
• W2976004908 hasConceptScore W2976004908C126322002 @default.
• W2976004908 hasConceptScore W2976004908C141071460 @default.
• W2976004908 hasConceptScore W2976004908C16005928 @default.
• W2976004908 hasConceptScore W2976004908C2775934546 @default.
• W2976004908 hasConceptScore W2976004908C2776715498 @default.
• W2976004908 hasConceptScore W2976004908C2776760755 @default.
• W2976004908 hasConceptScore W2976004908C2778570526 @default.
• W2976004908 hasConceptScore W2976004908C2778720950 @default.
• W2976004908 hasConceptScore W2976004908C2778751314 @default.
• W2976004908 hasConceptScore W2976004908C2779123688 @default.
• W2976004908 hasConceptScore W2976004908C2779134260 @default.
• W2976004908 hasConceptScore W2976004908C2779999465 @default.
• W2976004908 hasConceptScore W2976004908C2780439664 @default.
• W2976004908 hasConceptScore W2976004908C2781232998 @default.
• W2976004908 hasConceptScore W2976004908C3008058167 @default.
• W2976004908 hasConceptScore W2976004908C524204448 @default.
• W2976004908 hasConceptScore W2976004908C71924100 @default.
• W2976004908 hasConceptScore W2976004908C90924648 @default.
• W2976004908 hasLocation W29760049081 @default.
• W2976004908 hasLocation W29760049082 @default.
• W2976004908 hasOpenAccess W2976004908 @default.
• W2976004908 hasPrimaryLocation W29760049081 @default.
• W2976004908 hasRelatedWork W1013814 @default.
• W2976004908 hasRelatedWork W14446410 @default.
• W2976004908 hasRelatedWork W17011224 @default.
• W2976004908 hasRelatedWork W17470666 @default.
• W2976004908 hasRelatedWork W18358423 @default.
• W2976004908 hasRelatedWork W18363835 @default.
• W2976004908 hasRelatedWork W21319944 @default.
• W2976004908 hasRelatedWork W6658751 @default.
• W2976004908 hasRelatedWork W98198 @default.
• W2976004908 hasRelatedWork W17226944 @default.
• W2976004908 isParatext "false" @default.
• W2976004908 isRetracted "false" @default.
• W2976004908 magId "2976004908" @default.
• W2976004908 workType "article" @default.